Enteris BioPharma offers innovative formulation solutions built around its proprietary oral drug delivery technology platform – Peptelligence®. Since its founding in 2013, Enteris BioPharma has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective to enable the delivery of BSC III and IV compounds including peptides, peptidomimetics, and small molecules with low oral bioavailability. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square-foot GMP facility in Boonton, New Jersey, offering a range of manufacturing services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH). SWK offers Enteris with sound financial backing and long range planning support.
Enteris BioPharma is an independent, wholly-owned subsidiary of SWK Holdings Corporation, a publically traded company (Nasdaq: SWKH) and offers innovative formulation solutions and manufacturing services. Enteris has access to capital and resources that it can direct towards expansion and growth opportunities.